Pfizer said Tuesday it plans to file for full U.S. approval of its Covid-19 vaccine with German drugmaker BioNTech at the end of this month. If the FDA signs off, the company will be able to market the shot directly to consumers.
In releasing its first-quarter financial results, the company also reported $3.5 billion in first-quarter sales of its Covid-19 vaccine and reported earnings and revenue that beat Wall Street’s expectations.
Here’s how Pfizer did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:
Adjusted EPS: 93 cents per share vs 77 cents expected
Revenue: $14.58 billion vs. $13.51 billion expected
The company now expects full-year sales of $26 billion from the vaccine, up from its previous forecast of about $15 billion.
Shares of Pfizer rose 1.4% after the news.
Revenue from Pfizer’s oncology, internal medicine, hospital and rare disease units all rose by double digits during the quarter, according to the earnings report. The company’s inflammation and immunology unit generated about $1 billion in sales, a 9% increase from a year ago.
The company received U.S. authorization of its Covid vaccine in late December. Since then, the company has distributed millions of doses to the U.S., with the goal of delivering 300 million doses by the end of July.
Usually, it takes the Food and Drug Administration nearly a year or longer to determine whether a drug is safe and effective for use in the general public. But due to the once-in-a-century pandemic, which has killed nearly 600,000 Americans, the FDA permitted the use of the shots under an Emergency Use Authorization, or EUA.
An EUA grants conditional approval based on two months of data. It’s not the same as a Biologic License Application, or BLA, which requires six months of data and secures full approval.
